Understanding and targeting the mechanisms of cholangiocarcinoma development and treatment resistance
Project 2
This study is looking at how a specific signaling process helps cholangiocarcinoma, a cancer of the bile ducts, grow and survive, and it aims to test a new treatment that combines a special drug with regular chemotherapy to see if it can help patients feel better and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10935706 on NIH RePORTER |
What this research studies
This research investigates the cellular and molecular mechanisms that contribute to cholangiocarcinoma, a type of cancer affecting the bile ducts. It focuses on how YAP-TEAD signaling promotes cancer growth and survival, and aims to develop a new treatment approach by inhibiting this signaling pathway. The project includes preclinical studies and a first-in-human clinical trial to evaluate the safety and effectiveness of a novel TEAD inhibitor, CTX1009685, in combination with standard chemotherapy. Patients may benefit from insights into new therapeutic strategies that could improve treatment outcomes for cholangiocarcinoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced cholangiocarcinoma who have not responded well to standard treatments.
Not a fit: Patients with early-stage cholangiocarcinoma or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cholangiocarcinoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting YAP-TEAD signaling in cancer models, indicating potential for success in this novel approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Smoot, Rory — Mayo Clinic Rochester
- Study coordinator: Smoot, Rory
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.